US Bancorp’s Olema Pharmaceuticals OLMA Stock Holding History

US Bancorp’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.62K	Sell	511 -27	-5%	-$601	﹤0.01%	3447
2025 Q4	$13.4K	Buy	+538	New	+$9.57K	﹤0.01%	3229
2025 Q3	–	Sell	-30	Closed	-$128	–	4199
2025 Q2	$128	Buy	+30	New	+$134	﹤0.01%	4101
2025 Q1	–	Sell	-277	Closed	-$1.61K	–	4319
2024 Q4	$1.61K	Buy	+277	New	+$2.77K	﹤0.01%	3895
2024 Q2	–	Sell	-157	Closed	-$1.78K	–	4068
2024 Q1	$1.78K	Buy	157 +14	+10%	+$181	﹤0.01%	3744
2023 Q4	$2.01K	Buy	+143	New	+$1.92K	﹤0.01%	3703
2022 Q1	–	Sell	-3,106	Closed	-$29K	–	4161
2021 Q4	$29K	Buy	3,106 +2,923	+1,597%	+$60.6K	﹤0.01%	2918
2021 Q3	$5K	Sell	183 -115	-39%	-$3.1K	﹤0.01%	3652
2021 Q2	$8K	Buy	298 +280	+1,556%	+$7.97K	﹤0.01%	3492
2021 Q1	$1K	Buy	+18	New	+$771	﹤0.01%	3811

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

US Bancorp's OLMA Position: Q1 2026 in Review

US Bancorp reduced its Olema Pharmaceuticals (OLMA) stake by 5% in Q1 2026, selling an estimated $601 and leaving 511 shares worth $7.62K. The position accounts for ﹤0.01% of the portfolio, ranked #3447.

US Bancorp first reported a position in OLMA in Q1 2021 and has held it in 10 quarters since. The position peaked at $29K in Q4 2021. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

US Bancorp held 511 shares of Olema Pharmaceuticals worth $7.62K as of Q1 2026.
US Bancorp sold 27 Olema Pharmaceuticals shares in Q1 2026, an estimated $601.
Olema Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3447 holding.
US Bancorp first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
US Bancorp's Olema Pharmaceuticals position peaked at $29K in Q4 2021.
195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.